about
Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV InfectionThe clinically relevant pharmacogenomic changes in acute myelogenous leukemiaInhibition of mTOR-dependent autophagy sensitizes leukemic cells to cytarabine-induced apoptotic deathNew treatment strategies for HIV-positive cancer patients undergoing antiblastic chemotherapy.Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia.Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.PharmGKB summary: gemcitabine pathwaySAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.The mortality and response rate after FLANG regimen in patients with refractory/relapsed acute leukemia.Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia.Genetic and epigenetic variants contributing to clofarabine cytotoxicity.Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.Antiglioma effects of cytarabine on leptomeningeal metastasis of high-grade glioma by targeting the PI3K/Akt/mTOR pathway.SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.Replication fork collapse and genome instability in a deoxycytidylate deaminase mutant.Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.SNPing away to individualize induction therapy for acute myelogenous leukemia.Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells.Optimal AraC-Cytotoxicity to AML Cells Requires ERK5 Activity.An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance.Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function.Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.Pharmacogenomics of cytarabine in childhood leukemia.Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
P2860
Q26749811-AB917D87-E04F-4903-9FDB-7F996A9E2753Q27014790-130222CE-740C-4435-90E2-21CED75E322DQ28537581-7252ED4D-A642-4127-91B6-157972B0D653Q30244166-304C2B3C-9304-4D55-9354-BC4338424941Q33799305-7319578D-A2CD-4428-9510-5BB291E9A564Q33890300-25F30991-053C-496B-B1B2-9AD9E49E6626Q34435450-789DFD9E-7922-4061-9ED3-8EA42AAD5E60Q34547626-EC5CA3B7-2D14-4E25-97DF-EC0564E0C44EQ34548815-E9E8624A-8339-449D-8EE7-7F70A36C0157Q35114704-832BC402-2174-430C-8603-9792F2195786Q36201693-AD72D3BB-2FCE-4B78-B4FF-68AFC947246DQ36529403-57C84DBA-848A-47B1-933C-1667DD70AD51Q36873301-7CA58F27-B266-486B-92AF-33A99A873482Q36981855-FA4F3613-F62F-42F8-9B96-E4BE81DE205FQ37153800-F5342189-8F3D-4EAE-AB88-A5B7B1147958Q37720259-252DCC22-7453-430E-9CC8-7D47CCB63C6EQ37855227-361F20A5-E3CA-4250-9C31-88DF1BBFA273Q38078423-D625EBB3-B3C9-43FC-A2E8-C533959C0893Q38374457-25FE0BC4-80D6-44C4-8ABD-F93F614396E5Q38696870-6DB6B721-AAC0-4963-8DD1-91B029047D5BQ38757910-6F7E45C1-D671-4980-825A-02EB10EDE94FQ38763826-2DFD9E44-3972-480E-B442-B04B501162ABQ39401851-A391E7B2-AF15-4AC8-B4F9-52C273A4F6CCQ41582390-307A9C32-30D8-4EE4-8D39-B811BD4BE87FQ47137275-C5C1D09C-E4D1-4CE3-B48F-DA6E2F6E4BDEQ47375547-DD9D481B-AC4F-4A02-9FEA-C62A83E9FC9DQ47965783-4046C971-49DC-4B5C-9329-B5BA0DEBC5C4Q48066017-BA4ABDF8-5E9B-406B-9A9A-3F1D514AD8C8Q50090381-7AAAC2C4-6423-4C67-A41E-0876C5C98CF1Q50145888-290CD87E-1198-4392-9B38-CDD6907A4648Q51089294-5F37276A-994C-462B-99A1-BD8F04F991E4Q51283531-34C394CE-5AC0-4670-9E85-C8BF5F065B1FQ52431745-AC15858E-E217-4FD7-B80A-23167E9BE08CQ52716476-0DD3A759-329A-41F6-8A4C-50719E554D68Q53653257-4789E2BE-480C-4078-8C24-1041848EEC94Q53830656-BBA7342C-872F-436F-BCF1-3AD0EA17A1A7Q55283900-F1F195FC-9B95-4924-A7E0-AFE83E4145F1
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genetic factors influencing cytarabine therapy.
@en
Genetic factors influencing cytarabine therapy.
@nl
type
label
Genetic factors influencing cytarabine therapy.
@en
Genetic factors influencing cytarabine therapy.
@nl
prefLabel
Genetic factors influencing cytarabine therapy.
@en
Genetic factors influencing cytarabine therapy.
@nl
P2860
P356
P1433
P1476
Genetic factors influencing cytarabine therapy.
@en
P2093
Jatinder K Lamba
P2860
P304
P356
10.2217/PGS.09.118
P577
2009-10-01T00:00:00Z